Cargando…

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study

OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, T, Spaczynski, M, Kaufmann, A, Wysocki, J, Gałaj, A, Schulze, K, Suryakiran, P, Thomas, F, Descamps, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489326/
https://www.ncbi.nlm.nih.gov/pubmed/25208608
http://dx.doi.org/10.1111/1471-0528.13070
_version_ 1782379337238970368
author Schwarz, T
Spaczynski, M
Kaufmann, A
Wysocki, J
Gałaj, A
Schulze, K
Suryakiran, P
Thomas, F
Descamps, D
author_facet Schwarz, T
Spaczynski, M
Kaufmann, A
Wysocki, J
Gałaj, A
Schulze, K
Suryakiran, P
Thomas, F
Descamps, D
author_sort Schwarz, T
collection PubMed
description OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged 15–55 years, age-stratified into groups: 15–25, 26–45, and 46–55 years) who received three vaccine doses in the primary study. METHODS: Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME MEASURES: Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1. RESULTS: At 6 years after dose 1, all women were seropositive for anti-HPV–16 and ≥97% were seropositive for anti-HPV–18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV–16 and anti-HPV–18, respectively. In all age groups, GMTs were higher (anti-HPV–16, 9.3–45.1-fold; anti-HPV–18, 4.3–19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81–0.96 (anti-HPV–16) and 0.69–0.84 (anti-HPV–18). Exploratory modelling based on the 6–year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV–18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported. CONCLUSIONS: At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups.
format Online
Article
Text
id pubmed-4489326
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44893262015-07-07 Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study Schwarz, T Spaczynski, M Kaufmann, A Wysocki, J Gałaj, A Schulze, K Suryakiran, P Thomas, F Descamps, D BJOG Gynaecological Oncology OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged 15–55 years, age-stratified into groups: 15–25, 26–45, and 46–55 years) who received three vaccine doses in the primary study. METHODS: Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME MEASURES: Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1. RESULTS: At 6 years after dose 1, all women were seropositive for anti-HPV–16 and ≥97% were seropositive for anti-HPV–18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV–16 and anti-HPV–18, respectively. In all age groups, GMTs were higher (anti-HPV–16, 9.3–45.1-fold; anti-HPV–18, 4.3–19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81–0.96 (anti-HPV–16) and 0.69–0.84 (anti-HPV–18). Exploratory modelling based on the 6–year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV–18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported. CONCLUSIONS: At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups. John Wiley & Sons, Ltd 2015-01 2014-09-11 /pmc/articles/PMC4489326/ /pubmed/25208608 http://dx.doi.org/10.1111/1471-0528.13070 Text en © 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Gynaecological Oncology
Schwarz, T
Spaczynski, M
Kaufmann, A
Wysocki, J
Gałaj, A
Schulze, K
Suryakiran, P
Thomas, F
Descamps, D
Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title_full Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title_fullStr Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title_full_unstemmed Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title_short Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
title_sort persistence of immune responses to the hpv-16/18 as04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
topic Gynaecological Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489326/
https://www.ncbi.nlm.nih.gov/pubmed/25208608
http://dx.doi.org/10.1111/1471-0528.13070
work_keys_str_mv AT schwarzt persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT spaczynskim persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT kaufmanna persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT wysockij persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT gałaja persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT schulzek persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT suryakiranp persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT thomasf persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy
AT descampsd persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy